Lieutenant General (Ret) David F. Melcher serves as the Chairman of embecta, and was an Independent Director at Becton, Dickinson & Company (BD) from 2018-22, and at CR Bard Corporation (Bard) from 2014-2017. He also currently serves as an Independent Director at the United Services Automobile Association (USAA) and is on the Board of Managers for GM Defense, LLC, a wholly owned subsidiary of GM Corporation. He was also a former Lead Director of Cubic Corporation, a defense and transportation company that was bought by Veritas Capital in 2021.
In December 2017, LTG Melcher retired as President and Chief Executive Officer of Aerospace Industries Association, a trade association representing major aerospace and defense manufacturers and suppliers, a position he had held since 2015. From 2011 to 2015, he served as Chief Executive Officer, President and a director of Exelis Inc. (Exelis), a global aerospace defense, information and technology services company. Exelis, which was bought by Harris Corporation in 2015, was formerly a division of ITT Corporation that LTG Melcher led for three years before being spun off as a public company in 2011.
A graduate of both West Point and Harvard Business School, LTG Melcher provided over 32 years of distinguished service in the U.S. Army, having commanded in both light and heavy divisions, as Commander of the US Army Corps of Engineers Southwestern Division, and as the Army’s Deputy Chief of Staff for Programs.
David J. Albritton serves as a member of both the Corporate Governance and Nominating Committee and the Technology Committee at embecta and is the founder and chief executive officer of Nineteen88 Strategies. Prior to that, Mr. Albritton served most recently as vice president, communications, Worldwide Public Sector and Vertical Industries, at Amazon Web Services, and previously spent five years at General Motors (“GM”), most recently as president, lead executive and general manager for GM Defense.
Mr. Albritton began at GM following the sale of Exelis to Harris Corp. in 2015. He was Exelis’ Vice President and Chief Communications Officer, a role he assumed upon the company’s spinoff from ITT Corporation in 2011. He joined Exelis, then ITT Defense & Information Solutions, in November 2008 as the Vice President of Communications. Prior to that, he was Director of Media Relations in the Global Business Development and Government Relations office for Raytheon Company and has also held senior communications positions with United Way of America, Hewlett-Packard Company/Compaq Computer Corporation and Sears, Roebuck and Co.
Early in his career, Mr. Albritton spent 10 years as an officer in the U.S. Navy and served in the Pentagon as an official Navy Spokesman on the Navy News Desk and as the Flag Lieutenant / Aide for the U.S. Navy’s Chief of Information. He also served aboard USS PORTLAND (LSD 37) during Operations Desert Shield and Desert Storm.
He holds a Bachelor of Science in General Engineering from the U.S. Naval Academy in Annapolis, MD, as well as a Master of Science in Management from the Naval Postgraduate School in Monterey, CA. He has also completed executive education courses at Harvard University, Stanford University, and the Wharton School of Business.
Carrie L. Anderson serves as a member of both the Audit Committee and the Corporate Governance and Nominating Committee at embecta and is the executive vice president & chief financial officer for Integra LifeSciences (Nasdaq: IART). Prior to joining Integra in June 2019, she was vice president and controller of Dover Corporation (“Dover”). Previously, she was CFO of Dover’s Engineered Systems and initially joined Dover in October 2011 as CFO of Dover Pranging and Identification. Prior to Dover, Ms. Anderson spent six years as vice president and CFO of Delphi Product & Service Solutions, a division of Delphi Corporation. While at Delphi, she also held finance leadership positions at three other global operating divisions of Delphi.
Ms. Anderson started her career with General Motors after graduation from Purdue University with a Bachelor of Science in chemical engineering and earned her Master of Business Administration from Ball State University.
Robert (Bob) J. Hombach serves as the Chair of the Audit Committee and a member of the Compensation and Management Development Committee at embecta and is currently a board member of Aptinyx, Inc., BioMarin Pharmaceutical Inc., and CarMax, Inc. Until 2016, Mr. Hombach served as executive vice president, chief financial officer and chief operations officer of Baxalta, a biopharmaceutical company spun out from Baxter International, Inc. (NYSE: BAX).
He served as corporate vice president and chief financial officer of Baxter from July 2010 until the spinoff in 2015. From 2007 to 2011, Mr. Hombach served as treasurer of Baxter and from 2004 to 2007, he was vice president of finance, Europe, Middle East and Africa at Baxter. Prior to that, Mr. Hombach served in a number of finance positions of increasing responsibility in the corporate planning, manufacturing, operations and treasury areas at Baxter.
Mr. Hombach earned a Master of Business Administration from Northwestern University’s JL Kellogg Graduate School of Management, and a Bachelor of Science in Finance cum laude from the University of Colorado.
Devdatt (Dev) Kurdikar serves as the President and Chief Executive Officer of embecta. Previously, Dev was the President and CEO of Cardiac Science Corporation (CSC), a global leader in the manufacturing and marketing of automated external defibrillators (AEDs) for public access, education, police, and fire and rescue markets. CSC had been acquired by a private equity firm via bankruptcy proceedings, and under Dev’s leadership, CSC returned to profitable growth and was sold in a successful exit to ZOLL Medical.
Prior to that role, Dev was the Vice President and General Manager, Men’s Health, an important growth business within Urology and Pelvic Health at Boston Scientific Corp (NYSE: BSX). Dev was in the same role at American Medical Systems (AMS) and led the Men’s Health business through a significant business turnaround, and then the carve-out and sale to BSX, where Dev led the business through its integration into BSX. Before joining AMS, Dev served as Vice President, Marketing, Baxter International Inc. (NYSE: BAX), where he worked directly with the company’s top executives on a global commercial initiative to drive market access. Previously, he was the Vice President, Marketing for the Infusion Systems business for the U.S. region where he played a key role in stabilizing the business while under a consent decree, and launched a new wireless enabled infusion pump. In his 11 years with Baxter, Dev held leadership roles of increasing responsibility in finance, strategy and integration, R&D planning and operations. He began his career as a Senior Research Engineer at The Monsanto Company.
Dev holds a Bachelor in Chemical Engineering from the University of Bombay (India). He earned a Master of Science in Chemical Engineering from Washington State University (Washington), a Ph.D. in Chemical Engineering from Purdue University (Indiana), and a Master of Business Administration from Washington University (Missouri).
Milton M. Morris, Ph.D. serves as a member of both the Compensation and Management Development Committee and the Technology Committee at embecta and has been president and CEO of Neuspera Medical (“Neuspera”) since July of 2015. Prior to joining Neuspera, Dr. Morris was the senior vice president of research & development and emerging therapies at Cyberonics (now LivaNova). Dr. Morris was previously employed by Guidant Corporation and its successor, Boston Scientific Corporation, where he held several positions, including principal research scientist; director, research & development; and director, marketing.
Prior to joining Guidant, Dr. Morris spent five years working as a research assistant in the Medical Computing Laboratory at the University of Michigan in collaboration with the electrophysiology group at the University of Michigan Hospital and the Michigan Heart and Vascular Institute. Dr. Morris serves as a charter trustee for Northwestern University, where he chairs the Medicine Committee, and serves on the Board of Directors of Myomo, Inc. (NYSE: MYO).
Dr. Morris is a fellow in the American Institute for Medical and Biological Engineering (AIMBE), where he was inducted for contributions to developing and commercializing innovations in bioelectronic medicine.
Dr. Morris holds a Master in Business Administration from the Kellogg School of Management, a Master and Ph.D. in Electrical Engineering from the University of Michigan, and a Bachelor of Science in Electrical Engineering from Northwestern University.
Claire Pomeroy serves as the Chair of the Corporate Governance and Nominating Committee and a member of the Technology Committee at embecta and has served since 2013 as President of the Albert and Mary Lasker Foundation, a private foundation that seeks to improve health by accelerating support for medical research through recognition of research excellence, public education and advocacy. Prior thereto, she served as Dean and Vice Chancellor of the University of California, Davis School of Medicine. She is an elected member of the National Academy of Medicine. Dr. Pomeroy also served as a director of Becton, Dickinson & Company (BD) from 2014 until 2022.
Dr. Pomeroy is also a director of Haemonetics Corporation. She also serves on the Board of Directors of the Sierra Health Foundation, Center for Women in Academic Medicine and Science, iBiology/Science Communication Lab, the Science Philanthropy Alliance and Morehouse School of Medicine.
Karen N. Prange serves as the Chair of the Compensation and Management Development Committee and a member of the Audit Committee at embecta and has served as a director of ViewRay since June 2021, a director of Atricure since December 2019, a director of Nevro since December 2019 and WS Audiology since March 2020. She has served as Strategic Advisor to Nuvo Group, LLC, a medical device company, since September of 2019 and Industrial Advisor to EQT Group, a global investment organization, since March 2020. She served as a member of the Board of Directors of Cantel Medical, a medical equipment company, from October 2019 until June 2021.
Most recently, she was executive vice president and chief executive officer for the Global Animal Health, Medical and Dental Surgical Group at Henry Schein as well as a member of the Executive Committee. From 2012 to 2016, she served as senior vice president of Boston Scientific, and president of its Urology and Pelvic Health business. From 1995 to 2012, Ms. Prange held various roles of increasing leadership at Johnson & Johnson Company, most recently as General Manager of the Micrus Endovascular and Codman Neurovascular businesses.
Ms. Prange earned her Bachelor of Science in Business Administration with honors from the University of Florida and has completed executive education coursework at UCLA Anderson School of Business and Smith College.
Christopher R. Reidy serves as the Chair of the Technology Committee at embecta. Mr. Reidy served as the Executive Vice President, and Chief Administrative Officer and Chief Financial Officer at Becton, Dickinson & Company (BD) and Chief Financial Officer of Becton Dickinson & Company.
Prior to BD, Mr. Reidy served at ADP Corporation as corporate vice president and CFO for six years. Prior to ADP, Mr. Reidy served as CFO at NBA Properties, Inc., vice president, controller, chief accounting officer and division-level CFO roles at AT&T Corporation and audit partner at Deloitte & Touche. Mr. Reidy serves on the Board of Directors of Encompass Health Corporation and is a member of its Audit and Finance Committees.
He also sits on the Board of Directors of the Atlantic Health System and is a member of the Executive Committee, Chair of the Finance Committee and a member of the Quality Committee.
Mr. Reidy, a certified public accountant, earned a bachelor’s degree in accounting from St. Francis College and a master’s degree in business administration from Harvard University.